News DeskDubai, UAE – DP World’s Aviv Clinics, a pioneer in medical research and treatment, has announced groundbreaking findings from a longitudinal study on the treatment of long COVID syndrome. The study, conducted by esteemed hyperbaric medicine researchers Dr. Shai Efrati and Dr. Amir Hadanny, sheds light on the efficacy of hyperbaric oxygen therapy (HBOT) in alleviating symptoms and promoting tissue healing among long COVID patients.
The primary objective of the study, titled “Long-term outcomes of hyperbaric oxygen therapy in post COVID condition: longitudinal follow-up of a randomized controlled trial,” aimed to assess the long-term effects of a specific HBOT protocol on individuals suffering from long COVID syndrome. The study included 31 patients who underwent 40 daily sessions of HBOT, with assessments conducted more than one year after completing the treatment.
Previous research had already demonstrated significant improvements in cognitive function, psychiatric symptoms, fatigue, sleep quality, and pain among long COVID patients who underwent the unique HBOT protocol. The longitudinal follow-up revealed that these improvements persisted over the long term, indicating sustained benefits from the treatment.
Dr. Hadanny, Chief Medical Officer and Head of Research at DP World’s Aviv Clinics, emphasized the correlation between clinical improvement and neuroplasticity, highlighting the continuous gains in brain recovery observed among patients.
The results of the study indicate that HBOT can effectively enhance the quality of life, sleep, psychiatric well-being, and pain management for individuals grappling with long COVID symptoms. Moreover, the therapy facilitated the healing of damaged brain tissue, offering hope to thousands worldwide still grappling with post-COVID complications.
The unique HBOT protocol implemented at DP World’s Aviv Clinics involves repeated fluctuations in pressure and oxygen concentrations, triggering gene expression and metabolic pathways crucial for tissue regeneration. By delivering high oxygen concentrations, HBOT promotes oxygen delivery to tissues, aiding in the recovery of injured tissues and providing lasting improvement.
Dr. Shai Efrati, leader of the research group and chair of DP World’s Aviv Clinics Medical Advisory Board, stressed the clinic’s commitment to assisting those enduring long COVID symptoms, offering a promising treatment avenue that delivers sustained results.
DP World’s Aviv Clinics offers a comprehensive treatment program tailored to individual patient needs, combining HBOT with personalized cognitive and physical training and dietary plans. Prior to treatment, patients undergo a thorough assessment to ensure the suitability and sustainability of HBOT therapy.
This groundbreaking research signifies a significant advancement in the field of long COVID treatment, offering hope and relief to individuals worldwide grappling with persistent post-COVID symptoms.
